Publications: Flynn, Loren

2022

Theunissen, F., Flynn, L.L., Anderton, R.S. and Akkari, P.A. (2022) Short structural variants as informative genetic markers for ALS disease risk and progression. BMC Medicine, 20 (1). Art. 11.

Flynn, L.L., Li, R., Pitout, I.L., Aung-Htut, M.T., Larcher, L.M., Cooper, J.A.L., Greer, K.L., Hubbard, A., Griffiths, L., Bond, C.S., Wilton, S.D., Fox, A.H. and Fletcher, S. (2022) Single stranded fully Modified-Phosphorothioate oligonucleotides can induce structured nuclear inclusions, alter nuclear protein localization and disturb the transcriptome In Vitro. Frontiers in Genetics, 13 . Art. 791416.

2021

Theunissen, F., Anderton, R.S., Mastaglia, F.L., Flynn, L.L., Winter, S.J., James, I., Bedlack, R., Hodgetts, S., Fletcher, S., Wilton, S.D., Laing, N.G., MacShane, M., Needham, M., Saunders, A., MacKay-Sim, A., Melamed, Z., Ravits, J., Cleveland, D.W. and Akkari, P.A. (2021) Novel STMN2 variant linked to amyotrophic lateral sclerosis risk and clinical phenotype. Frontiers in Aging Neuroscience, 13 . Art. 658226.

Flynn, L.L., Mitrpant, C., Adams, A., Pitout, I.L., Stirnweiss, A., Fletcher, S. and Wilton, S.D. (2021) Targeted SMN exon skipping: A useful control to assess in vitro and in vivo splice-switching studies. Biomedicines, 9 (5). Article 552.

Foster, A.D., Flynn, L.L., Cluning, C., Cheng, F., Davidson, J.M., Lee, A., Polain, N., Mejzini, R., Farrawell, N., Yerbury, J.J., Layfield, R., Akkari, P.A. and Rea, S.L. (2021) p62 overexpression induces TDP-43 cytoplasmic mislocalisation, aggregation and cleavage and neuronal death. Scientific Reports, 11 (1). Art. 11474.

2020

Pytte, J., Anderton, R.S., Flynn, L.L., Theunissen, F., Jiang, L., Pitout, I., James, I., Mastaglia, F.L., Saunders, A.M., Bedlack, R., Siddique, T., Siddique, N. and Akkari, P.A. (2020) Association of a structural variant within the SQSTM1 gene with amyotrophic lateral sclerosis. Neurology Genetics, 6 (2). Art. e406.

Pytte, J., Flynn, L.L., Anderton, R.S., Mastaglia, F.L., Theunissen, F., James, I., Pfaff, A.ORCID: 0000-0002-2231-9800, Kõks, S., Saunders, A.M., Bedlack, R., Burns, D.K., Lutz, M.W., Siddique, N., Siddique, T., Roses, A.D. and Akkari, P.A. (2020) Disease-modifying effects of an SCAF4 structural variant in a predominantly SOD1 ALS cohort. Neurology Genetics, 6 (4). e470.

Theunissen, F., Flynn, L.L., Anderton, R.S., Mastaglia, F., Pytte, J., Jiang, L., Hodgetts, S., Burns, D.K., Saunders, A., Fletcher, S., Wilton, S.D. and Akkari, P.A. (2020) Structural variants may be a source of missing heritability in sALS. Frontiers in Neuroscience, 14 .

2019

Mejzini, R., Flynn, L.L., Pitout, I.L., Fletcher, S., Wilton, S.D. and Akkari, P.A. (2019) ALS genetics, mechanisms, and therapeutics: Where are we now? Frontiers in Neuroscience, 13 .

Pitout, I., Flynn, L.L., Wilton, S.D. and Fletcher, S. (2019) Antisense-mediated splice intervention to treat human disease: the odyssey continues. F1000Research, 8 .

Aung-Htut, M.T., McIntosh, C.S., Ham, K.A.ORCID: 0000-0002-7036-5334, Pitout, I.L., Flynn, L.L., Greer, K., Fletcher, S. and Wilton, S.D. (2019) Systematic approach to developing splice modulating antisense oligonucleotides. International Journal of Molecular Sciences, 20 (20). Article 5030.

2018

Flynn, L.L., Mitrpant, C., Pitout, I.L., Fletcher, S. and Wilton, S.D. (2018) Antisense oligonucleotide mediated terminal intron retention of the SMN2 transcript. Molecular Therapy - Nucleic Acids, 11 . pp. 91-102.